DocumentsDate added
Review article:
Mwahib Sid Ahmed Mohamed Osman Aldosh*
Affiliation:-
Assistant Professor, Radiological Sciences Department Applied Medical College - Najran University- Kingdom of Saudi Arabia
The name of the department(s) and institution(s) to which the work should be attributed:
Radiological Sciences Department Applied Medical College - Najran University- Kingdom of Saudi Arabia
Address reprint requests to
Dr. Mwahib Sid Ahmed Mohamed Osman Aldosh ,Ph.D
Assistant Professor, Radiological Sciences Department Applied Medical College-Najran University- Kingdom of Saudi Arabia
Article citation:
Mwahib A. Applications of Nanoparticles in Biomedical. J Pharm Biomed Sci. 2014;04(09):743-750. Available at www.jpbms.info
ABSTRACT
The application of nanomaterials for cancer therapy and for early diagnosis of pathologies has received considerable attention in recent years. Particularly in the field of biomedical with extensive applications. The wide interdisciplinary world of Nanoscience was experiencing a strong development during the last years. One exciting topic is the possibility of using nanoscale materials for biomedical applications. The application of nanotechnology to medicine, known as nanomedicine, concerns the use of precisely engineered materials at this length scale to develop novel therapeutic and diagnostic modalities. Recent improvements in engineering at the nanoscale level have lead to the development of a variety of new, novel nanoscale platforms (quantum dots, nanoshells, gold nanoparticles, paramagnetic nanoparticles, carbon nanotubes), which currently are under development and has profoundly studied. The emerging roles of these wide variety of applications, in biomedical imaging and therapeutic are the focus of this research, in addition to describing how nanoparticles can be used for targeted imaging and delivery of therapeutic agents and identify and discuss strategies to circumvent barriers to intratumoral delivery of nanoparticles.
KEYWORDS: Nanoparticles; applications; magnetic resonance imaging; cancer therapy; diagnostic imaging; drug deliver.
REFERENCES
1.R.V.Ramanujan , R. Narayan Magnetic Particles for Biomedical Applications, 2009, Springer,477-491
2.D.Nagesha, V.Torchillin, Multifunctional Magnetic Nanosystems for Tumor Imaging, Targeted Delivery, and Thermal Medicine, 2008, Springer Volume 4, http://dx.doi.org/10.1007/978-0-387-76554-9_13
3.A.J.Cole1 et al, Trends in Biotechnology, Cancer theranostics: the rise of targeted magnetic nanoparticles, 2011;29(7): No.7,323,http://dx.doi.org/10.1016/j.tibtech.2011.03.001
4.An-Hui Lu, E. L. Salabas and F. Schüth, Angew. Chem. Int. Magnetic Nanoparticles: Synthesis, Protection, Functionalization, and Application,.2007;46,:1222– 1244.http://dx.doi.org/10.1002/anie.200602866
5.Alexiou C., Schmidt A., Klein R., Hulin P.,Bergemann C., and Arnold W. Magnetic drug targeting: biodistribution and dependency on magnetic field strength, J. Magn. Magn. Mat.2002;252(1-3):363-366.
6.Kuznetsov A.A., Filippov V.., Alyautdin R.N.,Torshina N.L., Kuznetsov O.A. Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti cancer photodynamic drugs. J. Magn. Magn. Mat. 2001;225 (1-2):95-100. 7.Bulte J.W.M., de Cuyper M., Despres D. and Frank J.A. "Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent.J.Magn. Magn. Mat.1999;194(1-3):204-209.
8.Pardoe H., Clark P.R., St Pierre T.G., Moroz P., Jones S.K. A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors,Magnetic Resonance Imaging.2003;21(5):483-488.
9.Jordan A., Scholz R., Maier-Hauff K., Johannsen M., Wust P., Nadobny J., Schirra H., Schmidt H., Deger S., Loening S., Lanksch W. and Felix R. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J. Magn. Magn. Mat.2001; 225(1-2): 118-126.
10.Gruttner C., Rudershausen S. and Teller J. Improved properties of magnetic particles by combination of different polymer materials as particle matrix, J. Magn. Magn. Mat. 2001;225(1-2):1-7.
11.Pardoe H., Chua-anusorn W., St Pierre T.G. and Dobson J. Structural and magnetic properties of nanoscale iron oxide particles synthesized in the presence of dextran or polyvinyl alcohol. J.Magn. Magn. Mat. 2001;225 (1-2):41-46.
12.Ziolo R.R Self-stabilized aqueous ferrofluids. Properties and characteristics. European Cells and Materials,3:92-9.
13.Kratschmer W., Lamb L.D., Fostiropoulos K.and Huffman D.R. Solid C-60 - A new form of carbon, Nature.1990;347:354-358.
14.Cadek M., Murphy R., McCarthy B., Drury A., Lahr B., Barklie R.C., Panhuis M., Coleman J.N. and Blau W.J. Optimisation of the arc-discharge production of multi-walled carbon nanotubes. Carbon. 2002;40(6): 923-928.
15.Goldberg SN, Bonn J, Dodd G, et al. Society of Interventional Radiology Interventional Oncology Task Force: interventional oncology research vision statement and critical assessment of the state of research affairs. J Vasc Interv Radiol. 2005;16(10): 1287–1294.
16.Lim ZZ, Li JE, Ng CT, Yung LY, Bay BH. Gold nanoparticles in cancer therapy. Acta Pharmacol Sin. 2011;32:983-90.
17.Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part I: imaging. Cardiovasc Intervent Radiol. 2011; 34(2): 221–226.
18.Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part II: drug delivery, thermotherapy, and vascular intervention. Cardiovasc Intervent Radiol 2010 Sep 16. [Epub ahead of print]
19.Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011; 399(1):29–42.
20.Yang X Interventional molecular imaging. Radiology 2010; 254(3):651–654.
21.Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol.2010; 299(4):G807–G820.
22.Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008;26(11):612–621.
23.Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008; 3(2):133–149.
24.The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 2006;3:11.
25.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65(1–2):271–284.
26.Gohongi T, Fukumura D, Jain RK Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241–263.
27.Monsky WL, Mouta Carreira C, Tsuzuki Y,Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8(4):1008–1013.
28.Al-Abd AM, Hong KY, Song SC, Kuh HJ. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010; 142(1): 101–107.
29.Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5(2):79–88.
30.Germani G, Pleguezuelo M, Gurusamy K,.Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52(3):380–388.
31.Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007;99(14):1095–1106.
32.Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2):228–247.
33.Seibel RM, Melzer A, Schmidt A, Plabetamann J. Computed tomography- and magnetic resonance imaging: guided microtherapy. Semin Laparosc Surg 1997; 4(2):61–73.
34.Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2010 Nov 8. [Epub ahead of print].
35.Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60(10):1137–1152.
36.Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008; 70(3):726–734.
37.Lesinski GB, Sharma S, Varker KA,.Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices 2005;7(1):71–79.
38.Damascelli B, Cantù G, Mattavelli F,Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal—preliminary evidence of clinical activity. Cancer 2001;92(10):2592–2602.
39.Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010;299(4): G807–G820
40.Majoros IJ, Myc A, Thomas T, PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006;7(2): 572–579.
41.Cormode DP, Skajaa T, Fayad ZA,Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 2009;29(7):992–1000.
42.Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63(18):5838–5843.
43.Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998; 98(1):1–5.
44.Coto-García AM, Sote González E, Fernández-Argüelles MT, Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011; 399(1): 29–42.
45.Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010;299(4):G807–G820.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclosure forms provided by the authors are available with the full text of this article at jpbms.info
Copyright © 2014 Mwahib A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
Sadredin Rasi Hashemi 1, Hamid Noshad1,*, Hesam Rasul Amini²
Affiliation:-
1Chronic kidney Disease Research center, Tabriz University of Medical Sciences, Tabriz, Iran.
2Faculty of Medicine, Tabriz University of Medical sciences, Tabriz, Iran
The name of the department(s) and institution(s) to which the work should be attributed:
1.Chronic kidney Disease Research center, Tabriz University of Medical Sciences, Tabriz, Iran.
2.Faculty of Medicine, Tabriz University of Medical sciences, Tabriz, Iran
Address reprint requests to
Hamid Noshad.
Chronic kidney disease Research center, Tabriz university of medical sciences, Tabriz, Iran, Tel:+984113298247, Fax: +984113373966, Mobile: +989143115927.
Article citation:
Hashemi SR,Noshad H.Amini HR. Effect of hemodialysis with High-Flux filters on control of hyperphosphatemia in patients with end stage renal disease. J Pharm Biomed Sci. 2014; 04(09):737-742. Available at www.jpbms.info
ABSTRACT
Background: Hyperphosphatemia (HP) is one of the most important electrolyte disturbances in patients with end stage renal disease (ESRD). Its treatment is essential for controlling of Hyperparathyroidism, vessel calcifications and cardiovascular mortality. Current studies, evaluates the effect of high-flux hemodialysis on resistant hyperphosphatemia (HP) in ESRD patients.
Methods: Forty hemodialyzed patients with resistant HP were enrolled in a clinical trial study conducted at Tabriz University of medical sciences, Tabriz, Iran during February to October 2012. The eligible participants were randomly allocated to High and Low-flyx groups based on random block procedure produced by Random Allocation Software (RAS). All patients hemodialyzed for two months with the same filters (high efficienct). High-Flux (R60) filter in case group (n=20) and low-flux (R6) was used in the control group (n=20). Laboratory data and HD efficiency (KT/V) were compared before and at the end of the study. Quantitative values are compared by in depended student t-test and before-after values compared by paired t-test. Qualitative values compared by chi-square test and p-value less than 0.05 considered significant.
Results: There were significant differences in cholesterol, triglyceride, albumin and phosphate levels between both High-flux and Low-flux group and serum phosphate level diminished significantly in High-flux group (p=0.01,p=0.01,p=0.03,p=0.004 respectively).There was not any significant difference in HD efficacy between both groups (P=0.16).
Conclusion: High-Flux filter can reduce serum phosphate levels and improve lipid profile in ESRD patients with resistant hyperphosphatemia.
KEYWORDS: Hemodialysis; Hyperphosphatemia; High-Flux filter.
REFERENCES
1.Kuhlmann MK.Management of hyperphosphatemia. Hemodial Int. 2006;10(4):338-345.
2.Indridason OS, Quarles LD. Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther.2002; 9(3):184-192.
3.Francisco RC1, Aloha M, Ramón PS. Effects of high-efficiency postdilution online hemodiafiltration and high-flux hemodialysis on serum phosphorus and cardiac structure and function in patients with end-stage renal disease. Int Urol Nephrol. 2013;45(5):1373-1378.
4.Lornoy W, De Meester J, Becaus I, Billiouw JM, Van Malderen PA, Van Pottelberge M. Impact of convective flow on phosphorus removal in maintenance hemodialysis patients. J Ren Nutr. 2006;16(1):47-53.
5.Statopolsky E. New Development in Hyperphosphatemia Management. J AM Soc Nephrol, 2003,14, 5297-5299.
6.Mandolfo S, Imbasciati E.New dialysis therapy modalities: what role do they play in the hemodialysis patient's outcome?.G Ital Nefrol. 2002 ;19(1):22-30.
7.Tattersall J1, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii5-21.
8.Krane V, Krieter DH, Olschewski M, et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. 2007,79(2), 267-275.
9.Li Y, Wang Y, Lv J, Wang M.Clinical outcomes for maintenance hemodialysis patients using a high-flux (FX60) dialyzer.Ren Fail. 2013 ;35(9):1240-1245.
10.McIntyre CW. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin Dial.2007; 20(4), 337-341.
11.Makar SH, Sawires HK, Farid TM, Ali WM, Schaalan MF. Effect of High-flux Versus Low-flux Dialysis Membranes on Parathyroid Hormone. Iran J Kidney Dis. 2010 ;4(4):327-32.
12.Varela Lema L, Ruano Raviña A. Effectiveness and safety of different hemodialysis modalities: a review. J Nephrol,2007;20(5), 525-542.
13.Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. High-Flux Dialysis Membranes Improve Lipid Profile in Chronic Hemodialysis Patient. J Am Soc Nephrol,1995; 5, 1703-1708.
14.Ayli D, Ayli M, Azak A, et al. The effect of high-flux hemodialysis on renal anemia. J Nephrol,2004; 17(5), 701-706.
15.Schneider A1, Drechsler C, Krane V,et al. The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study. Clin J Am Soc Nephrol. 2012;7(1):52-59.
16.Rieu P. Treatment of hyperphosphatemia in hemodialysis patients. Nephrol Ther,2005,1(Suppl 4), S322-329.
17.Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int, 2004; 66, 355-366.
18.Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant,2004, 19, 293-296.
19.Hakim RM1, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int. 1996 ;50(2):566-570.
Copyright © 2014 Hashemi SR.,Noshad H.,Amini HR. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interest / Conflict of interest: None